Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine the clinical importance of distinguishing between HER2 mutations, amplifications, and HER2 protein overexpression in managing advanced NSCLC
• Integrate current data supporting HER2-directed therapies to develop personalized treatment plans for patients with advanced NSCLC harboring HER2 alterations
• Examine the role of TROP2-targeted antibody-drug conjugates in advanced NSCLC with and without targetable genomic alterations
• Implement evidence-based strategies to prevent and manage adverse events linked to HER2- and TROP2-directed therapies in NSCLC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.

Faculty:

Jacob Sands, MD

Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, Jazz Pharmaceuticals, Merck, Novartis, Pfizer, Sanofi, Medtronic; Grant/Research Funding: Amgen, Harpoon, Novartis

Marina Chiara Garassino, MD

Professor of Medicine
Director, Thoracic Oncology Program
The University of Chicago Medical Center
Chicago, IL

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Aptitude Health, AstraZeneca, Astro, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IASLC, Ideology, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati Therapeutics, Natera, Novocure, Nuvalent, Nuvation, OncoHost, Pfizer, Regeneron, Revolution Medicines, Roche, Summit, Takeda; Grant/Research Funding: AIFA, AIRC, Fondazione Veronesi, Horizon 2020, Italian Moh, TRANSCAN

Eric K. Singhi, MD

Thoracic Medical Oncologist
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, GSK, Janssen, Lilly, Novocure, Nuvalent, Nuvation Bio, Regeneron, Roche, Sandoz; Grant/Research Funding: Rexanna’s Foundation for Fighting Lung Cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including expert discussion of cases and answers to audience questions, go to https://www.gotoper.com/tb26-her2-trop2-nsclc-activity.

Release Date

March 11, 2026

Expiration Date

March 11, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.